Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400926 · ClinicalTrials.gov registry record
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
A clinical trial of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT07400926 is a study of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH) that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 30 participants, below the 62-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07400926, a study of Open Angle Glaucoma (OAG) and Ocular Hypertension (OH), is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
Conditions Studied
Interventions
- COMBINATION_PRODUCT Travoprost
Study Locations (1)
Wisconsin
- Glaukos Investigative Site - Kenosha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-17 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07400926
The ClinicalTrials.gov registry entry for NCT07400926 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (52% lower). The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which Travoprost is the first listed.
NCT07400926 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07400926 about?
NCT07400926 is a clinical study titled "Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg". Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)
What is the current status of trial NCT07400926?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-12-17. Estimated completion is 2026-07.
What conditions does trial NCT07400926 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH).
What interventions are being tested in trial NCT07400926?
The interventions under investigation include: Travoprost (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07400926?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07400926 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
RECRUITING · NA
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.